F Seiler1,2, F C Trudzinski3,4, M Kredel5, C Lotz5, P M Lepper3,4, R M Muellenbach6. 1. Klinik für Innere Medizin V - Pneumologie, Allergologie, Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str. 100, 66421, Homburg/Saar, Deutschland. frederik.seiler@uks.eu. 2. ECLS Center Saar, 66421, Homburg, Deutschland. frederik.seiler@uks.eu. 3. Klinik für Innere Medizin V - Pneumologie, Allergologie, Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str. 100, 66421, Homburg/Saar, Deutschland. 4. ECLS Center Saar, 66421, Homburg, Deutschland. 5. Universitätsklinikum Würzburg, Klinik und Poliklinik für Anästhesiologie, 97080, Würzburg, Deutschland. 6. Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Klinikum Kassel GmbH, 34125, Kassel, Deutschland.
Abstract
BACKGROUND: Hypercapnic respiratory failure is a frequent problem in critical care and mainly affects patients with acute exacerbation of COPD (AECOPD) and acute respiratory distress syndrome (ARDS). In recent years, the usage of extracorporeal CO2 removal (ECCO2R) has been increasing. OBJECTIVE: Summarizing the state of the art in the management of hypercapnic respiratory failure with special regard to the role of ECCO2R. METHODS: Review based on a selective literature search and the clinical and scientific experience of the authors. RESULTS: Noninvasive ventilation (NIV) is the therapy of choice in hypercapnic respiratory failure due to AECOPD, enabling stabilization in the majority of cases and generally improving prognosis. Patients in whom NIV fails have an increased mortality. In these patients, ECCO2R may be sufficient to avoid intubation or to shorten time on invasive ventilation; however, corresponding evidence is sparse or even missing when it comes to hard endpoints. Lung-protective ventilation according to the ARDS network is the standard therapy of ARDS. In severe ARDS, low tidal volume ventilation may result in critical hypercapnia. ECCO2R facilitates compensation of respiratory acidosis even under "ultra-protective" ventilator settings. Yet, no positive prognostic effects could be demonstrated so far. CONCLUSION: Optimized use of NIV and lung-protective ventilation remains standard of care in the management of hypercapnic respiratory failure. Currently, ECCO2R has to be considered an experimental approach, which should only be provided by experienced centers or in the context of clinical trials.
BACKGROUND:Hypercapnic respiratory failure is a frequent problem in critical care and mainly affects patients with acute exacerbation of COPD (AECOPD) and acute respiratory distress syndrome (ARDS). In recent years, the usage of extracorporeal CO2 removal (ECCO2R) has been increasing. OBJECTIVE: Summarizing the state of the art in the management of hypercapnic respiratory failure with special regard to the role of ECCO2R. METHODS: Review based on a selective literature search and the clinical and scientific experience of the authors. RESULTS: Noninvasive ventilation (NIV) is the therapy of choice in hypercapnic respiratory failure due to AECOPD, enabling stabilization in the majority of cases and generally improving prognosis. Patients in whom NIV fails have an increased mortality. In these patients, ECCO2R may be sufficient to avoid intubation or to shorten time on invasive ventilation; however, corresponding evidence is sparse or even missing when it comes to hard endpoints. Lung-protective ventilation according to the ARDS network is the standard therapy of ARDS. In severe ARDS, low tidal volume ventilation may result in critical hypercapnia. ECCO2R facilitates compensation of respiratory acidosis even under "ultra-protective" ventilator settings. Yet, no positive prognostic effects could be demonstrated so far. CONCLUSION: Optimized use of NIV and lung-protective ventilation remains standard of care in the management of hypercapnic respiratory failure. Currently, ECCO2R has to be considered an experimental approach, which should only be provided by experienced centers or in the context of clinical trials.
Authors: Divay Chandra; Jason A Stamm; Brian Taylor; Rose Mary Ramos; Lewis Satterwhite; Jerry A Krishnan; David Mannino; Frank C Sciurba; Fernando Holguín Journal: Am J Respir Crit Care Med Date: 2011-10-20 Impact factor: 21.405
Authors: Daniele Camboni; Alois Philipp; Matthias Lubnow; Thomas Bein; York Zausig; Michael Hilker; Bernhard Flörchinger; Leopold Rupprecht; Andreas Keyser; Reinhard Kobuch; Dirk Lunz; Simon Schopka; Assad Haneya; Christof Schmid; Thomas Müller Journal: ASAIO J Date: 2012 Nov-Dec Impact factor: 2.872
Authors: Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler Journal: N Engl J Med Date: 2000-05-04 Impact factor: 91.245
Authors: M Confalonieri; G Garuti; M S Cattaruzza; J F Osborn; M Antonelli; G Conti; M Kodric; O Resta; S Marchese; C Gregoretti; A Rossi Journal: Eur Respir J Date: 2005-02 Impact factor: 16.671
Authors: Giles J Peek; Miranda Mugford; Ravindranath Tiruvoipati; Andrew Wilson; Elizabeth Allen; Mariamma M Thalanany; Clare L Hibbert; Ann Truesdale; Felicity Clemens; Nicola Cooper; Richard K Firmin; Diana Elbourne Journal: Lancet Date: 2009-09-15 Impact factor: 79.321
Authors: Thomas Bein; Frank Weber; Alois Philipp; Christopher Prasser; Michael Pfeifer; Franz-Xaver Schmid; Bernhard Butz; Dietrich Birnbaum; Kai Taeger; Hans J Schlitt Journal: Crit Care Med Date: 2006-05 Impact factor: 7.598